SYNLOGIC, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.58 USD | -1.25% |
|
-5.95% | -58.96% |
| 03-21 | Synlogic, Inc. Announces Board Changes | CI |
| 03-21 | North American Morning Briefing : Investors -2- | DJ |
Presentation Operator MessageOperator (Operator)Good morning, and welcome to Synlogic, Inc.'s ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Synlogic, Inc. is a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases. The Company is focused on rare metabolic disorders, with its lead program, labafenogene marselecobac (SYNB1934), studied in Synpheny-3, a global, pivotal Phase 3 study for patients with phenylketonuria (PKU), and SYNB1353, a potential treatment for homocystinuria (HCU). The Company's early-stage pipeline includes product candidates for enteric hyperoxaluria, gout, and cystinuria, and has been fueled by a reproducible, proprietary approach that creates gastrointestinal (GI)-restricted, oral medicines with new enzymatic pathways designed to consume or produce specific biological targets. It designs, develops and manufactures these drug candidates, which are produced by applying genetic engineering to well-characterized probiotics. The Companyâs preclinical work includes additional metabolic disease research.
Calendar
2024-08-07
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
HOLD
Number of Analysts
2
Last Close Price
1.6
USD
Average target price
1
USD
Spread / Average Target
-37.50%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -58.96% | 18.64M | |
| +63.72% | 62.59B | |
| -2.01% | 41.18B | |
| +44.76% | 40.29B | |
| -8.93% | 27.9B | |
| +12.38% | 26.21B | |
| -22.15% | 19.09B | |
| +3.77% | 13.08B | |
| +25.52% | 12.26B | |
| +26.99% | 12.05B |
- Stock Market
- Equities
- SYBX Stock
- News Synlogic, Inc.
- Transcript : Synlogic, Inc. - Shareholder/Analyst Call
